In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways

Long-term Survival in Metastatic Malignant Melanoma: Ipilimumab Followed by Vemurafenib in a Patient with Brain Metastasis

(2014) Ozan Balakan et al.   INTERNAL MEDICINE

EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis

(2013) Krishna M. Talasila et al.   ACTA NEUROPATHOLOGICA

Automated Tracking of Nanoparticle-labeled Melanoma Cells Improves the Predictive Power of a Brain Metastasis Model

(2013) T. Sundstrom et al.   CANCER RESEARCH

Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study

(2013) Reinhard Dummer et al.   EUROPEAN JOURNAL OF CANCER

Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases

(2013) Frits Thorsen et al.   JOURNAL OF CONTROLLED RELEASE

Successful Treatment With Vemurafenib in BRAF V600K–Positive Cerebral Melanoma Metastasis

(2013) Andrea Forschner et al.   JAMA Dermatology

BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma

(2012) Y Shao et al.   CELL DEATH AND DIFFERENTIATION

Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

(2012) M. A. Davies et al.   CLINICAL CANCER RESEARCH

Melanoma brain metastasis: overview of current management and emerging targeted therapies

(2012) Ekokobe Fonkem et al.   Expert Review of Neurotherapeutics

Neoadjuvant Treatment of a Solitary Melanoma Brain Metastasis With Vemurafenib

(2012) Grant R. Kolar et al.   JOURNAL OF CLINICAL ONCOLOGY

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

(2011) K. H. T. Paraiso et al.   CANCER RESEARCH

Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease

(2011) A. Vultur et al.   CLINICAL CANCER RESEARCH

Towards new therapeutic approaches for malignant melanoma

(2011) Ivan Pacheco et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Using genetics and genomics strategies to personalize therapy for cancer: Focus on melanoma

(2010) Katherine L. Nathanson   BIOCHEMICAL PHARMACOLOGY

Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail

(2010) Gajanan S. Inamdar et al.   BIOCHEMICAL PHARMACOLOGY

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo

(2010) Jia-lu Jin et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

PLX4032: does it keep its promise for metastatic melanoma treatment?

(2010) Elisabeth Livingstone et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

(2010) Jill C Rubinstein et al.   Journal of Translational Medicine

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients

(2010) J. Wang et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

(2009) M. A. Davies et al.   CLINICAL CANCER RESEARCH

BRAF Signaling and Targeted Therapies in Melanoma

(2009) Nathalie Dhomen et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma

(2009) Viktória Lázár et al.   MODERN PATHOLOGY

The Vascular Basement Membrane as “Soil” in Brain Metastasis

(2009) W. Shawn Carbonell et al.   PLoS One

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations

(2008) J LOPICCOLO et al.   DRUG RESISTANCE UPDATES

Mammalian target of rapamycin as a therapeutic target in oncology

(2008) Robert T Abraham et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA